The first year-long CGM implant developer isn’t done yet

Senseonics launched Eversense 365, the first implantable continuous glucose monitor (CGM) designed to function for a full year, in 2024. Unlike transcutaneous rivals from Abbott and Dexcom that use small needles to measure interstitial glucose, the Eversense system uses a different sensing approach. The company is advancing the implantable CGM category as a differentiated alternative in the glucose monitoring market.